Introduction {#S0001}
============

Oxygen free radical (OFR), produced by burns, is an important factor in tissue damage, which can increase vascular permeability and cell membrane lipid peroxidation and cause local and systemic inflammation.[@CIT0001],[@CIT0002] The previous studies reminded that burns can promote lipid peroxidation.[@CIT0003]--[@CIT0005] Lipid peroxidation is an autocatalytic reaction which induces toxic metabolism and cell apoptosis. In addition, the application of antioxidants after burns has protective effects on oxidative tissue damage and organ failure.[@CIT0006]--[@CIT0008] To improve treatment effects and prevent OFR injuries, antioxidants must be used as early as possible in severely burned patients.[@CIT0003],[@CIT0006]

Tiopronin \[N-(2-mercaptopropionyl)-glycine\] is a commonly used antioxidant with a free mercapto group. Some reports indicated that it is a free radical scavenger that prevents cell membrane damage from free radicals. Tiopronin has been widely used in the treatment of various diseases.[@CIT0009],[@CIT0010] But to date, there are no reports of tiopronin used in burn patients. In addition, vitamin C is water soluble and in the aqueous phase it is an antioxidant. It not only scavenges oxygen radicals, such as superoxide (O~2~^−^), hydroxyl radical (OH^−^), and singlet oxygen (O^−^), but along with citamin E, it also has a chain breakage-type antioxidizing effect and terminates oxygen radical reaction inside and outside of cell membranes.[@CIT0011] It was widely publicized as a universal antioxidant, which in high doses is a useful and safe therapy for the burn shock period.[@CIT0012]--[@CIT0015]

As previous work has relied on animal-based models with little clinical information, in this study, we investigated the protective effects of tiopronin against oxidative stress in severely burned patients, using treatment with vitamin C and standard treatment as control.

Methods {#S0002}
=======

The Institutional Ethics Committee of Ji Shui Tan Hospital approved this clinical study, and informed consent was obtained from the patient or legal next of kin.

From July 2011 to September 2016, patients aged between 16 and 65 years, with more than 30% total body surface area (TBSA) burns, were admitted to our burn unit less than 6 hrs postburn. They had no liver or kidney dysfunction. Thirty-six consecutive patients were randomized into 3 groups: group A (n=12), group B (n=12), and group C (n=12). One patient in group A, who died on the second day after admission because of severe inhalation injury, was excluded. The profiles of the three groups were similar regarding age, gender, BSA burns and percent of full-thickness burn, the presence of inhalation injury and whether they required mechanical ventilation (*P*\>0.05,[Table 1](#T0001){ref-type="table"}). Fluid infusion was started immediately after admission according to the Evans formula but with real burns TBSA. The hourly infusion volume was adjusted to maintain stable hemodynamic values (systolic blood pressure\>12 kPa, heart rate\<120/min, central venous pressure 0.49 kPa--0.98 kPa) and adequate urine output (0.5--1.0 mL/kg/hr). Group A was treated with tiopronin intravenously for 7 days (15 mg/kg.24 hrs, Hennan Province Xinyi Pharmaceutical Co., Ltd, XinXiang City, China), while group B was treated with vitamin C (in the form of L-ascorbic acid) intravenously for 7 days (792 mg/kg.24 hrs, Beijing Double-Crane Pharmaceutical Co., Ltd, Chaoyang District, Beijing, China). Treatment was divided into 4 infusions, group C was treated with standard therapy (including rapid and enough fluid resuscitation according to the Evans formula, nutrition support by enteral nutrition, systemic and topical application of antibiotics, critical care by cardiac monitoring, and so on), and the other 2 groups also received standard therapy.Table 1Patient demographicsGroup AGroup BGroup C*F* value*P-*valueNumber of patients111212Gender (male/female)8/37/59/3Age (years)33.5±9.5^\#^31.7±11.129.8±8.11.74＞0.05Percent TBSA burned53.0±10.7^\#^50.7±11.851.4±7.61.85＞0.05Percent TBSA with full-thickness burns20.3±8.1^\#^23.0±8.423.8±5.41.46＞0.05Admission time postburn (hrs)2.1±1.0^\#^2.4±1.31.9±1.51.78＞0.05Percent (number) of patients with inhalation injury\*27.3% (3)^\#^25.0% (3)33.3% (4)2.34＞0.05Percent (number) of requiring mechanical ventilation27.3 (3)^\#^16.7% (2)25.0% (3)2.73＞0.05[^1][^2]

A series of blood samples were collected before treatment; and after treatment at 24 and 48 hrs. Immediately after collection, serum was removed by centrifuge and stored at −20°C as soon as possible until assayed. Samples from eight normal healthy adult volunteers (5 males, 3 females, 18\~30 years of age) were also measured.

Malondialdehyde (MDA) level was measured by thiobarbituric acid use MDA kit, and superoxide dismutase (SOD) activity was detected by inhibiting nitrite formation use SOD kit (both kits were issued by Nanjing Jiancheng Bioengineering Institute, Xuanwu District, Nanjing City, China), operated strictly according to the instructions of the kit. Add 0.5ml serum to the MDA kit, measuring optical density (OD) value of MDA at 532 nm using Microplate Reader (BECAM-CULTER, Atlanta Vision Center, Atlanta, Georgia, USA), and also add 0.5ml serum to the SOD kit, measuring OD value of SOD at 550 nm using Microplate Reader, and calculating the concentration of MDA and SOD in serum samples. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine (Cr), creatine kinase-MB (CK-MB), cystatin C (CysC), and cardiac troponinI (CTnI) were determined using automated analyzer (MONRH, BECAM-CULTER and BECK MAN DXC800, USA), operated strictly according to the instructions of the kit (the kits were issued by BECAM-CULTER, Atlanta Vision Center, Atlanta, Georgia, USA). Biochemical indexes of liver, kidney, and heart were determined directly using automated analyzer. The resuscitation fluid volume requirement for 3 groups was calculated during the first 24 hrs.

Statistical analysis {#S0002-S2001}
--------------------

Statistical analysis was performed using SPSS 16.0 software. Values were expressed as mean ± SD. Categorical variables were compared by Chi-square test, repeated-measures ANOVA were compared among groups, and least significant difference (LSD) test for multiple comparisons between groups, *P*\<0.05 was considered significant.

Results {#S0003}
=======

MDA levels in serum were found to be markedly higher in severely burned patients than in healthy volunteers (*P*\<0.01), while treatment reversed these elevations back to normal. In contrast, SOD levels in serum were discernibly lower in burned patients compared to healthy volunteers (*P*\<0.01), while treatment inhibited the depletion of SOD stores. These changes were more obvious in group A and group B compared to that in group C (*P*\<0.05), and these changes were more obvious in group A compared to that in group B (*P*\<0.05) at 48 hrs after treatment ([Table 2](#T0002){ref-type="table"}).Table 2The serum levels of SOD and MDASOD ($\documentclass[12pt]{minimal}
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The resuscitation fluid volume requirement to maintain adequate stable haemodynamic parameters and urine output in the first 24 hrs in group A = TBSA% × body weight (kg)×1.46 mL (colloid to electrolyte ratio 1:2) + water 2000 mL, whereas group B required = TBSA% × body weight (kg)×1.48 mL (colloid to electrolyte ration 1:2) + water 2000 mL, while group C required = TBSA% × body weight (kg)×1.64 mL (colloid to electrolyte ration 1:2) + water 2000 mL. Compared to group C, it required less resuscitation fluid volume to maintain adequate stable haemodynamic and urine output in group A and group B (*P*\<0.05), but there was no significant difference of resuscitation fluid volume requirement between group A and group B in the first 24 hrs (*P*\>0.05).

Discussion {#S0004}
==========

OFRs are now considered to play an important role in increasing vascular permeability and lipid peroxidation of the cell membrane and initiating local and systemic inflammation.[@CIT0001],[@CIT0002] Burn injury may activate neutrophils to produce additional OFRs via the "respiratory burst" mechanism, utilizing the membrane-bound nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex.[@CIT0016] However, major burn injuries cause hypovolemia, which requires massive fluid resuscitation, yet adequate fluid resuscitation is often delayed for hours. Restoration of blood flow is necessary, but this restoration may lead to a reperfusion injury. Various studies indicate that OFRs are involved in ischemia--reperfusion injury.[@CIT0002],[@CIT0008],[@CIT0017] Activation of xanthine oxidase via ischemia--reperfusion may generate mass superoxide radicals, subsequently causing the peroxidation of membrane phospholipids, leading to cell death, tissue damage, and distant organ dysfunction. In addition, studies suggested that antioxidants or free radical scavengers are administered after burns and exert protective effects against burn-induced oxidative tissue damage and multiple-organ failure.[@CIT0002],[@CIT0003],[@CIT0006]

Measuring OFRs is difficult in clinic because it has a short half-life. MDA is oneterminal metabolite of unsaturated fatty acids peroxidized by attacks from free radicals and is considered to be an index of the level of OFR, thiobarbituric acid method is one of the commonly used methods for the detection of MDA.[@CIT0003] SOD is an important reducing agent and antioxidant involved in maintaining the cellular oxidation reduction balance, which can also scavenge free radicals produced by oxidative stress, and may be useful as an antioxidant and as a cytoprotective agent.[@CIT0018] Combined detection of MDA and SOD can detect OFR injury more effectively.[@CIT0019],[@CIT0020] The present study showed that SOD was markedly depleted and MDA was increased discernibly in severely burned patients, indicating that lipid peroxidation was also increased and that the capacity of antioxidation decreased following severe burns. This result is consistent with the findings of previous studies.[@CIT0006],[@CIT0017]

Vitamin C is water soluble and in the aqueous phase is an antioxidant; it not only scavenges oxygen radicals, such as superoxide (O~2~^−^), hydroxyl radical (OH^−^), and singlet oxygen (O^−^), but along with vitamin E, it also has a chain breakage-type antioxidizing effect and terminates oxygen radical reaction inside and outside of cell membranes.[@CIT0011] Vitamin C can interact with and remove oxygen radicals from vitamin E free radicals and thus regenerate vitamin E. Therefore, vitamin C protects both the capillary endothelium within the burned tissue and the circulating cells. Several experimental and clinical studies have indicated that high-dose vitamin C therapy in severe burns not only reduces the requirement for resuscitation fluid , but also alleviates burn edema and lipid peroxidation.[@CIT0012],[@CIT0013] The optimum dose of Vitamin C for humans has not yet been determined, but a previous study demonstrated that high dose vitamin C (66 mg/kg.hour) administration to humans is safe.[@CIT0013],[@CIT0015],[@CIT0021] This dosage was used in the present study, but was divided into 4 infusions.

Tiopronin, (N-(2-mercaptopropionyl)-glycine), is a commonly used antioxidant with a free thiol (sulphydryl) group. This molecule, in common with other sulfhydryl (SH)-containing compounds, not only scavenges oxygen radicals, such as superoxide (O~2~^−^) and hydroxyl radical (OH^−^), but also improves the capacity of SOD to scavenge oxygen radicals; moreover, its SH groups maintain the intracellular glutathione level. Tiopronin has several advantages over other sulphydryl compounds as a possible clinical antidote and is already used clinically to treat various hepatic disorders, nephrotoxicity, and cystine urolithiasis.[@CIT0009],[@CIT0010],[@CIT0022] This greatly simplifies its introduction as a protective drug. So far, tiopronin has caused very few adverse effects in clinical use. Previous studies have demonstrated that the dose tiopronin (15 mg/kg.24 hrs) administration to humans is safe,[@CIT0009],[@CIT0010] this dosage was used in the present study.

The present study showed that after being treated with tiopronin or vitamin C, levels of SOD were markedly increased; levels of MDA were obviously decreased; and heart, liver, and kidney function was improved. These changes were more obvious in tiopronin group compared with vitamin C group at 48 hrs after treatment. While tiopronin provided more effective protection compared to being treated with vitamin C, the mechanisms remain to be determined.

CTnI is considered the most sensitive and special target to evaluate myocardial injury.[@CIT0023] In this study, CTnI level was obviously decreased when treated with tiopronin compared to vitamin C at 48 hrs after treatment; however, the levels of CK-MB and LDH had no obvious difference. CysC is a more sensitive index of early renal function injury than BUN and Cr.[@CIT0024] Our data reminded that BUN and Cr levels had no obvious difference in tiopronin group, vitamin C group, and the standard control group at 48 hrs after treatment. However, compared with the standard control group, the level of CysC was markedly decreased in tiopronin group and vitamin C group.

Previous studies have indicated that vitamin C inhibits the increased vascular permeability in burned patients, and subsequently reduces the volume of required fluid resuscitation.[@CIT0012],[@CIT0013],[@CIT0021] The present study suggested that compared with the standard control group, it required less resuscitation fluid volume to maintain adequate stable hemodynamic and urine output in tiopronin group and vitamin C group. However, there was no significant difference in resuscitation fluid volume requirement between tiopronin group and vitamin C group in the first 24 hrs. The above results indicated that tiopronin could reduce the volume of required fluid resuscitation, while maintaining adequate stable hemodynamic parameters and urine output.

OFR produced by burns is an important factor in tissue damage and organ dysfunction. Treatment with tiopronin could exert protective effects against burn-induced oxidative tissue damage and multiple-organ dysfunction, and also could reduce the volume of required fluid resuscitation in severely burned patients, and may be a useful therapy for the burn shock period.
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[^1]: **Notes:** \*Bronchoscopic diagnosis. ^\#^*P*＞0.05 vs group B and group C.

[^2]: **Abbreviation:** TBSA, total body surface area.

[^3]: **Notes:** SOD treatment factor main effects, *F*=40.78, *P*\<0.01, time factor main effect, *F*=443.65, *P*\<0.01, interaction between the two, *F*=11.59, *P*\<0.01；MDA treatment factor main effects, *F*=44.84, *P*\<0.01, time factor main effect, *F*=541.44, *P*\<0.01, interaction between the two, *F*=38.51, *P*\<0.01; \**P*\<0.01 vs normal, ^Δ^*P*\<0.05 vs group B, ^\#^*P*\<0.05 vs group C.

[^4]: **Abbreviations:** SOD, superoxide dismutase; MDA, malondialdehyde.

[^5]: **Notes:** ALT treatment factor main effects, *F*=5.64 *P*\<0.01, time factor main effect, *F*=76.49, *P*\<0.01, interaction between the two, *F*=44.10, *P*\<0.01；AST treatment factor main effects, *F*=5.35, *P*\<0.01, time factor main effect, *F*=97.86, *P*\<0.01, interaction between the two, *F*=14.75, *P*\<0.01; \**P*\<0.01 vs normal, ^Δ^*P*\<0.05 vs group B, ^\#^*P*\<0.05 vs group C.

[^6]: **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[^7]: **Notes:** BUN treatment factor main effects, *F*=0.38, *P*\>0.05, time factor main effect, *F*=82.57, *P*\<0.01, Interaction ietween the two, *F*=1.81, *P*\>0.05；CRE treatment factor main effects, *F*=2.77, *P*\>0.05, time factor main effect, *F*=190.64, *P*\<0.01, interaction between the two, *F*=1.30, *P*\>0.05; \**P*\<0.01 vs normal, ^Δ^*P*\>0.05 vs group B, ^\#^*P*\>0.05 vs group C.

[^8]: **Abbreviations:** BUN, blood urea nitrogen; CRE, creatinine.

[^9]: **Notes:** CK-MB treatment factor main effects, *F*=4.14, *P*\<0.05, Time factor main effect, *F*=90.46, *P*\<0.01, interaction between the two, *F*=2.38, *P*\>0.05; LDH treatment factor main effects, *F*=6.63, *P*\<0.01, time factor main effect, *F*=329.83, *P*\<0.01, interaction between the two, *F*=7.05, *P*\<0.01; \**P*\<0.01 vs normal, ^Δ^*P*\>0.05 vs group B, ^\#^*P*\<0.05 vs group C.

[^10]: **Abbreviations:** LDH, lactate dehydrogenase; CK-MB, creatine kinase MB.

[^11]: **Notes:** cTnI treatment factor main effects, *F*=43.1, *P*\<0.01, time factor main effect, *F*=30.26, *P*\<0.01, interaction between the two, *F*=14.41, *P*\<0.01; CysC treatment factor main effects, *F*=7.16, *P*\<0.01, time factor main effect, *F*=173.77, *P*\<0.01, interaction between the two, *F*=5.81, *P*\<0.01; \**P*\<0.01 vs normal, ^Δ^*P*\<0.05 vs group B, ^\#^*P*\<0.01 vs group C.

[^12]: **Abbreviations:** cTnI, cardiac troponinI; CysC, cystatin C.
